<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805465</url>
  </required_header>
  <id_info>
    <org_study_id>FirstWenzhouMU001</org_study_id>
    <nct_id>NCT02805465</nct_id>
  </id_info>
  <brief_title>Comparison of His Bundle Pacing and Bi-Ventricular Pacing in Heart Failure With Atrial Fibrillation</brief_title>
  <official_title>Comparison of His Bundle Pacing (HBP) and Bi-Ventricular Pacing(BiVP) in Heart Failure (HF) Patients With Atrial Fibrillation (AF) Who Need Atrial-Ventricular Node (AVN) Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HT-Med Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Wenzhou Medical Univeristy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, prospective, randomized cross-over study to compare His Bundle
      Pacing (HBP) with Bi-Ventricular Pacing (BiVP) in HF Patients with AF who need
      atrial-ventricular node ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion and exclusion criteria will be enrolled into the study. In
      the study, both atrial-ventricular node(AVN) ablation and Cardiac Resynchronization Therapy
      (CRT) implantation are performed with HBP lead implanted and connected with the A port of CRT
      device. Followed with successful AVN ablation, HBP lead and CRT implantation, patients are
      1:1 randomized into BiVP and HBP group for 9 months and then crossover for another 9 months.
      The primary end points of the study is the change of left ventricular ejection fraction
      (LVEF) in both HBP and BiV pacing group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of LVEF(%) from baseline in HBP and BiV Group</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of 6min walking distance (m) from the baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LV end diastolic diameter(mm) from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LV end systolic diameter(mm) from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of heart failure hospitalization after the procedure group</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of Life</measure>
    <time_frame>18 months</time_frame>
    <description>The Short Form (36) Health Survey (SF-36) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Average sensing amplitude (V)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of average pacing threshold (V)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of average pacing impedance (ohm)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of New York Heart Association (NYHA) Classification from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with heart failure hospitalization after the procedure</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>HBP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiVP Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT Device and Bi-ventricular pacing</intervention_name>
    <description>Bi-ventricular pacing by a CRT device</description>
    <arm_group_label>HBP Group</arm_group_label>
    <arm_group_label>BiVP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT Device and His-bundle Pacing</intervention_name>
    <description>His-bundle pacing by a CRT device through the pacing lead at His-bundle region</description>
    <arm_group_label>HBP Group</arm_group_label>
    <arm_group_label>BiVP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years old

          -  Subject or authorized legal guardian or representative has signed and dated the
             Informed

          -  Subject is expected to remain available for follow-up visits at the study center

          -  Subjects with heart failure NYHA Class II-IV

          -  Subjects with LVEF no greater than 40%

          -  Subjects with persistent atrial fibrillation or atrial flutter with uncontrolled
             ventricular rate

        Exclusion Criteria:

          -  Subjects with the width of ECG Q, R, S wave (QRS) complex &gt;120ms

          -  Subjects with life expectancy less than 3 years

          -  Subjects with mechanical right heart valve

          -  Subjects with primary valvular disease

          -  Subjects with heart transplant, or is currently on a heart transplant list

          -  Subjects who are pregnant, or of childbearing potential and not on a reliable form of
             birth control

          -  Subjects with significant renal dysfunction, as manifested by serum creatinine level
             &gt;2.5 mg/dl or ≥275 μmol/L or estimated glomerular filtration rate (GFR) ≤30
             mL/min/1.72 m2, which is documented within the 30 days prior to enrollment or at
             baseline.

          -  Subjects with significant hepatic dysfunction, as evidenced by a hepatic function
             panel (serum) &gt; 3 times upper limit of normal, which is documented within the 30 days
             prior to enrollment or at baseline.

          -  Subjects with chronic or treatment-resistant severe anemia (hemoglobin &lt;10.0 g/dL),
             which is documented within the 30 days prior to enrollment or at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijian Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wenzhou 1st Affliated Hopsital, Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weijian Huang, MD</last_name>
    <phone>+86 138-0669-1086</phone>
    <email>weijianhuang69@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lan Su, MD</last_name>
    <phone>+86 137-3874-2616</phone>
    <email>2512057600@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affliated Hospital, Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijian Huang, MD</last_name>
      <phone>+86 138-0669-1086</phone>
      <email>weijianhuang69@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lan Su</last_name>
      <phone>+86 137-3874-2616</phone>
      <email>2512057600@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Weijian Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lan Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Wenzhou Medical Univeristy</investigator_affiliation>
    <investigator_full_name>Weijiang Huang</investigator_full_name>
    <investigator_title>Dean of Cardiology, First Affiliated Hospital of Wenzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>CRT</keyword>
  <keyword>BiVP</keyword>
  <keyword>HBP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

